Inoue Takuro, Hirai Hisao, Shima Ayako, Suzuki Fumio, Yamaji Masayuki, Fukushima Takanori, Matsuda Masayuki
Department of Neurosurgery, Subarukai Kotoh Kinen Hospital, 2-1 Hiramatsu-cho, Higashiohmi-shi, Shiga, 527-0134, Japan.
Department of Cardiology, Subarukai Kotoh Kinen Hospital, Higashiohmi-shi, Shiga, Japan.
Acta Neurochir (Wien). 2017 Nov;159(11):2127-2135. doi: 10.1007/s00701-017-3325-7. Epub 2017 Sep 14.
There is still no clear guideline for surgical treatment for patients with medically refractory trigeminal neuralgia (TN). When it comes to which surgical treatment to choose, microvascular decompression (MVD) or Gamma Knife surgery (GKS), we should know the long-term outcome of each treatment.
We analyzed 179 patients undergoing MVD and 52 patients undergoing GKS followed for 1 year or longer. We evaluated the patient's neurological status including pain relief, complications and recurrence. Results were assessed with Barrow Neurological Institute (BNI) pain intensity and facial numbness scores. Overall outcomes were compared between the two groups based on pain relief and complications.
BNI pain intensity and facial numbness scores at the final visit were significantly lower in the MVD group than in the GKS group (P < 0.001, P = 0.04, respectively). Overall outcomes were superior following MVD than following GKS (P < 0.001). Following whichever treatment, there were initially high rates of pain-free status "without medication": 96.6% in the MVD group and 96.2% in the GKS group. However, 6.1% in the MVD group and 51.9% in the GKS group fell into a "with medication" state within median periods of 1.83 and 3.92 years, respectively (P < 0.001). Kaplan-Meier analysis revealed that pain recurred more often and later in the GKS group than in the MVD group (P < 0.001).
Considering the long-term outcomes, MVD should be chosen as the initial surgical treatment for patients with medically refractory TN.
对于药物难治性三叉神经痛(TN)患者的外科治疗,目前仍没有明确的指南。在选择何种外科治疗方法时,即微血管减压术(MVD)还是伽玛刀手术(GKS),我们应该了解每种治疗方法的长期疗效。
我们分析了179例行MVD的患者和52例行GKS且随访1年或更长时间的患者。我们评估了患者的神经状态,包括疼痛缓解情况、并发症和复发情况。结果采用巴罗神经学研究所(BNI)疼痛强度和面部麻木评分进行评估。基于疼痛缓解情况和并发症,对两组的总体结果进行比较。
末次随访时,MVD组的BNI疼痛强度和面部麻木评分显著低于GKS组(分别为P < 0.001,P = 0.04)。MVD后的总体结果优于GKS(P < 0.001)。无论采用哪种治疗方法,最初“无需药物”的无痛状态发生率都很高:MVD组为96.6%,GKS组为96.2%。然而,MVD组6.1%的患者和GKS组51.9%的患者分别在1.83年和3.92年的中位期内进入“需药物”状态(P < 0.001)。Kaplan-Meier分析显示,GKS组疼痛复发比MVD组更频繁且更晚(P < 0.001)。
考虑到长期疗效,MVD应被选为药物难治性TN患者的初始外科治疗方法。